- Home
- POWW vs XFOR Comparison
POWW vs XFOR Comparison
Compare POWW & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POWW | XFOR |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 288.5M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | POWW | XFOR |
|---|---|---|
| Price | $2.19 | $2.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $11.60 |
| AVG Volume (30 Days) | 533.2K | ★ 880.2K |
| Earning Date | 11-16-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.61 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | $108.00 | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $1.49 | $2.43 |
| 52 Week High | $2.67 | $4.83 |
Technical Indicators
Market Signals| Indicator | POWW | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 34.19 |
| Support Level | $1.94 | N/A |
| Resistance Level | $2.23 | $4.40 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 30.95 | 34.40 |
Price Performance
Historical ComparisonAbout POWW AMMO Inc.
Outdoor Holding Co the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketplace segment consists of the GunBroker e-commerce marketplace. The company generates the majority of its revenue from the Ammunition segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.